GWS
ALNY icon

Greykasell Wealth Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Greykasell Wealth Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32K Hold
4
– – ﹤0.01% 532
2025
Q4 		$1.59K Hold
4
– – ﹤0.01% 460
2025
Q3 		$1.82K Buy
+4
New +$1.63K ﹤0.01% 371

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Greykasell Wealth Strategies's ALNY Position: Q1 2026 in Review

Greykasell Wealth Strategies held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 4 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

Greykasell Wealth Strategies first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.82K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Greykasell Wealth Strategies held 4 shares of Alnylam Pharmaceuticals worth $1.32K as of Q1 2026.
  • Greykasell Wealth Strategies left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #532 holding.
  • Greykasell Wealth Strategies first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Greykasell Wealth Strategies's Alnylam Pharmaceuticals position peaked at $1.82K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.